Alexion’s Investigation Reveals ‘Inappropriate’ Conduct, Nothing Illegal
Alexion’s internal investigation of so-called pull-in sales found no improper financial activity, but will require employee training and amended procedures to avoid further violations of company policies.
You may also be interested in...
The company's long-acting C5 complement inhibitor ALXN1210 demonstrated non-inferiority to Soliris in a Phase III trial, which should help the company defend against anticipated competition to its blockbuster franchise.
The rare disease specialist’s new CEO is former Baxalta CEO Ludwig Hantson, who takes over the helm immediately after a leadership shakeup coinciding with an audit investigation.
A difficult December for Alexion sees a pivotal study of its blockbuster Soliris failing to show any benefit in preventing delayed graft function in kidney transplant patients, an indication for which there are no approved treatments.